Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripertamab in CIDP
NCT06858722Phase 3Not yet recruiting
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of ripertamab in chronic inflammatory demyelinating polyneuropathy (CIDP). Planned start Mar 2025; status: not yet recruiting.
02
Drugs
ripertamab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT06858722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06858722.